Fig. 3: Assessment of the characteristics of engineered iPS cells.
From: Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout
a, A microscopy image of iPS cells and clones A7 and B2 with HLA-A, HLA-B and HLA-DRA knocked out. Scale bars, 500 μm. b, Alkaline phosphatase (AP) staining image of iPS cells, YiP3 and clones A7 and B2. Scale bars, 500 μm. c, Real-time PCR data for the pluripotency markers, such as OCT4, SOX2, KLF4, LIN28 and NANOG, and three-germ layer differentiation markers, such as SOX17, BRACHYURY and PAX6, in YiP3 and clones A7 and B2. d, Flow cytometry data for pluripotency markers, such as tumor rejection antigen 1-60 (TRA-1-60), NANOG, stage-specific embryonic antigen 1 (SSEA4), OCT4 and the negative marker CD34 in YiP3 and clones A7 and B2. e, The immunocytochemistry images demonstrating the expression of markers (PAX6) for ectoderm, (BRACHYURY) for mesoderm and (SOX17) for endoderm, and 4',6-diamidino-2-phenylindole (DAPI) for nuclear staining following differentiation into the three germ layers using YiP3 and clones A7 and B2. Scale bars, 200 μm.
